drugset

drugset / Trial / NCT07016269

A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

NCT07016269 ↗

Phase 4 Recruiting 358 enrolled Myungmoon Pharma. Co. Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia

Timeline

Start: 2025-08-29
Primary completion: 2026-06
Completion: 2026-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CnU	Unknown	500 mg	Oral

Indications